| scholarly article | Q13442814 |
| P356 | DOI | 10.1152/AJPGI.00167.2011 |
| P8608 | Fatcat ID | release_dw3srvzlvbdvdbvl6eldxhoqpu |
| P932 | PMC publication ID | 3233787 |
| P698 | PubMed publication ID | 21903764 |
| P50 | author | Janelle C Arthur | Q45517844 |
| P2093 | author name string | Angel A Isidro | |
| Caroline B Appleyard | |||
| Myrella L Cruz | |||
| Christian Jobin | |||
| Claudio De Simone | |||
| P2860 | cites work | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis | Q24234806 |
| VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation | Q24651289 | ||
| Gastrointestinal microflora, food components and colon cancer prevention | Q24654943 | ||
| Probiotics promote gut health through stimulation of epithelial innate immunity | Q30437282 | ||
| Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity | Q34140317 | ||
| Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis | Q34192292 | ||
| Detection of alkaline sphingomyelinase activity in human stool: proposed role as a new diagnostic and prognostic marker of colorectal cancer | Q34410661 | ||
| Alkaline sphingomyelinase activity is decreased in human colorectal carcinoma | Q34416042 | ||
| Alkaline sphingomyelinase: an old enzyme with novel implications | Q34516413 | ||
| Molecular basis of the potential of vitamin D to prevent cancer | Q34717856 | ||
| Epidemiology of inflammatory bowel disease | Q74474663 | ||
| Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study | Q77474250 | ||
| The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis | Q84290217 | ||
| The effects of probiotics on colon cancer development | Q34903381 | ||
| Pathology of mouse models of intestinal cancer: consensus report and recommendations | Q35075841 | ||
| Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease | Q35209644 | ||
| Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. | Q35233808 | ||
| Conjugated linoleic acids: are they beneficial or detrimental to health? | Q35937622 | ||
| Molecular biology of dysplasia and cancer in inflammatory bowel disease | Q36585424 | ||
| Familial adenomatous polyposis is associated with a marked decrease in alkaline sphingomyelinase activity: a key factor to the unrestrained cell proliferation? | Q36619585 | ||
| Probiotics and the incidence of colorectal cancer: when evidence is not evident. | Q36720519 | ||
| Angiogenesis in inflammatory bowel disease. | Q37069325 | ||
| Microbes and colorectal cancer: is there a relationship? | Q37292427 | ||
| Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon | Q37305789 | ||
| AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. | Q37689250 | ||
| Intestinal inflammation and cancer | Q37870432 | ||
| Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence | Q40417738 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| Tissue-nonspecific alkaline phosphatase is activated in enterocytes by oxidative stress via changes in glycosylation. | Q42474636 | ||
| Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in C57BL/10J mice | Q43095847 | ||
| Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis | Q43162041 | ||
| Vitamin D receptor expression is associated with colon cancer in ulcerative colitis | Q43269945 | ||
| Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine | Q43275123 | ||
| Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease | Q43275854 | ||
| High-dose probiotics for the treatment of active pouchitis | Q43353488 | ||
| Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. | Q43746137 | ||
| Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease | Q45153369 | ||
| Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 | ||
| Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease | Q46495260 | ||
| The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis | Q46753164 | ||
| Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer | Q46897570 | ||
| Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier | Q46930482 | ||
| Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells | Q47945739 | ||
| Chronic inflammation alters the contribution of neurokinin receptor subtypes to epithelial function in rat colon | Q48597049 | ||
| Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study | Q48677169 | ||
| Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. | Q53622713 | ||
| Role of alkaline phosphatase in colitis in man and rats. | Q53968888 | ||
| Microbiota in pediatric inflammatory bowel disease. | Q54432000 | ||
| Microflora in colorectal cancer: a friend to fear. | Q54669007 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Corticosteroids Modulate Angiogenic Soluble Factors in Ulcerative Colitis Patients | Q59509470 | ||
| Effects of the Probiotic Formulation VSL#3 on Colitis in Weanling Rats | Q61992575 | ||
| Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs | Q71949328 | ||
| Cancer risk in patients with inflammatory bowel disease: a population-based study | Q73592419 | ||
| P433 | issue | 6 | |
| P921 | main subject | probiotics | Q1816730 |
| inflammation | Q101991 | ||
| P304 | page(s) | G1004-13 | |
| P577 | publication date | 2011-09-08 | |
| P1433 | published in | American Journal of Physiology - Gastrointestinal and Liver Physiology | Q15765756 |
| P1476 | title | Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer | |
| P478 | volume | 301 |
| Q88871339 | Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice |
| Q59796435 | Antibiotic-Induced Dysbiosis of Gut Microbiota Impairs Corneal Nerve Regeneration by Affecting CCR2-Negative Macrophage Distribution |
| Q92757722 | Antibiotic-induced dysbiosis of gut microbiota impairs corneal development in postnatal mice by affecting CCR2 negative macrophage distribution |
| Q91699243 | Beneficial effect of synbiotics on experimental colon cancer in rats |
| Q34779160 | Bifidobacterium infantis attenuates colitis by regulating T cell subset responses |
| Q36031099 | Colonic macrophage polarization in homeostasis, inflammation, and cancer |
| Q47818880 | Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches. |
| Q64891815 | Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the serum biochemical parameters, and the vitamin D and leptin receptor genes on mice colon cancer. |
| Q38702152 | Evolving Roles of Probiotics in Cancer Prophylaxis and Therapy |
| Q37254281 | Fecal metabolome of the Hadza hunter-gatherers: a host-microbiome integrative view |
| Q35069458 | Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia |
| Q28730618 | Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria |
| Q60511100 | Inflammation and Colorectal Cancer |
| Q36597803 | Inflammation and colorectal cancer: colitis-associated neoplasia |
| Q53575927 | Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3. |
| Q38186066 | Intestinal alkaline phosphatase: novel functions and protective effects |
| Q36891360 | Manipulation of the Gut Microbiota Reveals Role in Colon Tumorigenesis |
| Q91975122 | Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential |
| Q26861193 | Modification in the diet can induce beneficial effects against breast cancer |
| Q26741117 | Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease |
| Q64903251 | Novel cancer therapy targeting microbiome. |
| Q36127288 | Nuclear receptors as modulators of the tumor microenvironment |
| Q34967922 | Nutrigenetics, nutrigenomics and inflammatory bowel diseases |
| Q38021933 | Nutritional and probiotic supplementation in colitis models |
| Q49483670 | Pretreatment with probiotic Bifico ameliorates colitis-associated cancer in mice: Transcriptome and gut flora profiling. |
| Q92865756 | Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy |
| Q94527883 | Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases |
| Q58693358 | Probiotics and Their Potential Preventive and Therapeutic Role for Cancer, High Serum Cholesterol, and Allergic and HIV Diseases |
| Q50024692 | Role of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review |
| Q35713388 | Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans. |
| Q38825153 | The Potential Role of Probiotics in Cancer Prevention and Treatment |
| Q34092270 | The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner |
| Q50899710 | The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis. |
| Q90148527 | The Role of Probiotics in Colorectal Cancer Management |
| Q34944458 | The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis |
| Q92180014 | The microbiome, cancer, and cancer therapy |
| Q38068230 | The new prophylactic strategy for colon cancer in inflammatory bowel disease by modulating microbiota |
| Q37685309 | Thymoquinone potentiates chemoprotective effect of Vitamin D3 against colon cancer: a pre-clinical finding |
| Q94551426 | Understanding the microbiome: a primer on the role of the microbiome in colorectal neoplasia |
| Q35010644 | VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer |
| Q47136291 | Vitamin D Axis in Inflammatory Bowel Diseases: Role, Current Uses and Future Perspectives |
| Q64263827 | Vitamin D Deficiency in the Gulf Cooperation Council: Exploring the Triad of Genetic Predisposition, the Gut Microbiome and the Immune System |
| Q28087758 | Vitamin D and immunity |
| Q33758617 | Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases |
Search more.